Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

Table 4 Results of the Meta-Regression Analysis

	Moderator	k	B	SE	p
All vaccines recipients, 1^st dose	Age	60	-0.004	0.002	.082
All vaccines recipients, 1^st dose	%females	76	0.048	0.034	.162
Placebo recipients, 1^st dose	Age	19	-0.001	0.004	.896
Placebo recipients, 1^st dose	%females	20	-0.013	0.382	.973
All vaccines recipients, 2^nd dose	Age	17	0.001	0.003	.965
All vaccines recipients, 2^nd dose	%females	25	0.134	0.189	.485
BNT162b2, 1^st dose	Age	26	-0.005	0.002	.041
BNT162b2, 1^st dose	%females	33	0.115	0.188	.545
BNT162b2, 2^nd dose	Age	10	-0.006	0.004	.213
BNT162b2, 2^nd dose	%females	15	0.160	0.320	.625
PiCoVacc, 1^st dose	%females	6	0.242	0.272	.424
ChAdOx1, 1^st dose	Age	8	-0.012	0.009	.231
ChAdOx1, 1^st dose	%females	12	0.688	0.435	.145

ISSN: 1129-2377